Physician profile
Christopher Mcgreevy
NPI 1942599550
$1,238.07
in general payments reported to CMS, 2019-2025
11 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $232 · 2022: $15.41 · 2023: $74.94 · 2024: $110 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $481.21 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $231.97 | 2020 | |
| Davol INC. | $174.77 | 2023-2025 | Phasix Mesh, Channel Drain |
| Merit Medical Systems INC | $150.53 | 2024-2025 | Savi Scout |
| Merck Sharp & Dohme LLC | $43.58 | 2024-2025 | Lynparza, Keytruda |
| Hologic Sales and Service, LLC | $34.85 | 2024-2025 | Sentimag, Localizer, Trunode |
| Axogen | $30.60 | 2025 | |
| Abbvie INC. | $29.74 | 2025 | |
| Sanara Medtech INC. | $25.87 | 2024 | Celleraterx |
| Acera Surgical, INC. | $19.54 | 2025 | Restrata Wound Matrix |
| Mindray Ds USA, INC. | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcgreevy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.